미국의 이상혈색소증 시장 규모, 점유율, 동향 분석 리포트 : 유형별, 진단별, 요법별, 지역별, 부문별 예측(2024-2030년)

U.S. Hemoglobinopathies Market Size, Share & Trends Analysis Report By Type (Thalassemia, Sickle Cell Disease), By Diagnosis (Thalassemia, Sickle Cell Disease), By Therapy, By Region, And Segment Forecasts, 2024 - 2030

US $ 3,950 ￦ 5,715,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,950 ￦ 7,162,000

Printable PDF (5-User License)

PDF 보고서를 동일 기업의 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,950 ￦ 10,055,000

Printable PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

미국의 이상혈색소증 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 리포트에 따르면 미국의 이상혈색소증 시장 규모는 2030년까지 68억 5,000만 달러에 달하며, 2024-2030년의 CAGR은 12.5%로 성장할 것으로 예측되고 있습니다.

겸상적혈구증 및 지중해빈혈과 같은 비정상적인 헤모글로빈 질환의 유병률 증가는 중요한 시장 성장 촉진요인입니다. 유전자 검사, 산전 검사 등 진단 기술의 발전으로 인해 헤모글로빈 이상 질환의 조기 발견이 향상되고 있습니다. 또한 유전자 치료 및 CRISPR-Cas9와 같은 유전자 편집 기술과 같은 새로운 치료 옵션에 대한 연구가 진행되고 있으며, 향후 더 효과적인 치료법을 기대할 수 있습니다.

헤모글로빈혈증에 대한 인식을 높이고 환자들의 치료 접근성을 개선하기 위한 정부 구상이 증가하면서 시장을 촉진하는 데 중요한 역할을 하고 있습니다. R&D에 대한 자금 지원도 이 분야의 기술 혁신을 가속화하고 있습니다.

제약회사, 연구기관, 의료기관의 협력은 새로운 치료법 개발을 촉진하고 환자 치료를 개선할 수 있습니다. 각 회사의 강점을 활용하는 파트너십은 의약품 개발을 가속화하고 치료 결과를 개선할 수 있습니다.

미국 이상혈색소증 시장 보고서 - 주요 내용

• 겸상적혈구증은 2023년 60.1%의 점유율을 차지하며 유형별 부문을 지배하고 예측 기간 중 가장 빠른 CAGR로 성장할 것으로 예상됩니다. 이러한 성장은 겸상적혈구증(SCD) 치료에 대한 접근성을 개선하기 위한 바이오 제약사 및 비영리 단체의 구상 증가에 기인합니다.
• 겸상적혈구증 진단 분야는 2023년 가장 큰 시장을 차지했습니다. 차세대 염기서열 분석 및 분자진단과 같은 유전자 검사 방법의 발전이 이 부문의 성장을 가속하고 있습니다.
• 겸상적혈구증 치료 분야는 2023년 가장 큰 시장을 차지했습니다. 유전자 이상을 교정하기 위한 유전자 치료 및 표적 치료와 같은 혁신적인 치료법의 승인 확대가 시장 성장을 촉진하고 있습니다.
• 지난 4월, 유전체 제약사 Sangamo Therapeutics는 SAR445136 겸상적혈구증 프로그램을 Sanofi에서 Sangamo로 이전한다고 발표했습니다. 이번 전환은 겸상적혈구증에 대한 유전자 편집 치료제 개발에 있으며, 중요한 진전입니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 미국의 이상혈색소증 시장 변수, 동향, 범위

• 시장 계통 전망
  • 모시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 촉진요인 분석
  • 시장 억제요인 분석
• 미국의 이상혈색소증 시장 분석 툴
  • 업계 분석 - Porter's Five Forces 분석
  • PESTEL 분석

제4장 미국의 이상혈색소증 시장 : 유형 추정·동향 분석

• 시장 점유율, 2023년과 2030년
• 부문 대시보드
• 유형별 시장 전망
• 시장 규모와 예측 및 동향 분석, 2018-2030년

제5장 미국의 이상혈색소증 시장 : 진단 추정·동향 분석

• 시장 점유율, 2023년과 2030년
• 부문 대시보드
• 진단별 시장 전망
• 시장 규모와 예측 및 동향 분석, 2018-2030년

제6장 미국의 이상혈색소증 시장 : 요법 추정·동향 분석

• 시장 점유율, 2023년과 2030년
• 부문 대시보드
• 요법별 시장 전망
• 시장 규모와 예측 및 동향 분석, 2018-2030년

제7장 경쟁 구도

• 주요 시장 참여 기업별 최근 동향과 영향 분석
• 기업/경쟁의 분류
• 벤더 구도
• 기업 개요
  • Sangamo Therapeutics, Inc.
  • Global Blood Therapeutics, Inc.
  • bluebird bio, Inc.
  • Emmaus Life Sciences Inc.
  • Pfizer, Inc.
  • Novartis AG
  • Prolong Pharmaceuticals, LLC
  • Bioverativ Inc.
  • Celgene Corp.

KSA

영문 목차

영문목차

U.S. Hemoglobinopathies Market Growth & Trends:

The U.S. hemoglobinopathies market size is anticipated to reach USD 6.85 billion by 2030, growing at a CAGR of 12.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of hemoglobinopathies, such as sickle cell disease and thalassemia, is a significant market driver. Advances in diagnostic techniques, such as genetic testing and prenatal screening, have improved the early detection of hemoglobinopathies. In addition, ongoing research into novel treatment options, including gene therapy and gene editing technologies like CRISPR-Cas9, holds promise for more effective therapies in the future.

The growing government initiatives to raise awareness about hemoglobinopathies and improved access to care for affected individuals play a crucial role in driving the market. Funding support for research and development efforts also accelerates innovation in this field.

Collaboration between pharmaceutical companies, research institutions, and healthcare providers fosters the development of new therapies and enhances patient care. Partnerships that leverage companies' strengths can accelerate drug development and improve treatment outcomes.

U.S. Hemoglobinopathies Market Report Highlights:

• Sickle cell disease type dominated the type segment with 60.1% share in 2023 and is expected to grow at fastest CAGR over the forecast period. The growth is attributed to the increasing Initiatives of Biopharmaceutical Companies and Nonprofit Organizations Driving Improved Access to Sickle Cell Disease (SCD) Treatment.
• The sickle cell disease diagnosis segment held the largest market in 2023. Advancements including genetic testing methods such as next-generation sequencing and molecular diagnostics are propelling the segment growth.
• The sickle cell disease therapy segment held the largest market in 2023. The growing approval of innovative therapies, such as gene therapies and targeted treatments, designed to modify genetic abnormalities are propelling market growth.
• In April 2022, Sangamo Therapeutics, a genomic medicines company, announced the transition of its SAR445136 sickle cell disease program from Sanofi to Sangamo. This transition marks a significant step in the development of a gene-edited therapy for sickle cell disease.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Diagnosis
  • 1.2.3. Therapy
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Volume price analysis (Model 2)
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. Diagnosis outlook
  • 2.2.3. Therapy outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Hemoglobinopathies Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. U.S. Hemoglobinopathies Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's Five Forces
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. U.S. Hemoglobinopathies Market: Type Estimates & Trend Analysis

• 4.1. Type Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. U.S. Hemoglobinopathies Market by Type Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
  • 4.4.1. Thalassemia
    • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Sickle cell disease
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Other Hb variants
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Hemoglobinopathies Market: Diagnosis Estimates & Trend Analysis

• 5.1. Diagnosis Market Share, 2023 & 2030
• 5.2. Segment Dashboard
• 5.3. U.S. Hemoglobinopathies Market by Diagnosis Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
  • 5.4.1. Thalassemia
    • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.2. Alpha
    • 5.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.2.2. Blood test
    • 5.4.1.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.2.3. Genetic test
    • 5.4.1.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.2.4. Prenatal genetic test
    • 5.4.1.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.2.5. Pre-implantation genetic test
    • 5.4.1.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.2.6. Electrophoresis
    • 5.4.1.2.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.2.7. Others
    • 5.4.1.2.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.3. Beta
    • 5.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.3.2. Blood test
    • 5.4.1.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.3.3. Genetic test
    • 5.4.1.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.3.4. Prenatal genetic test
    • 5.4.1.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.3.5. Pre-implantation genetic test
    • 5.4.1.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.3.6. Electrophoresis
    • 5.4.1.3.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.3.7. Others
    • 5.4.1.3.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Sickle cell disease
    • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2.2. Blood test
    • 5.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2.3. Genetic test
    • 5.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2.4. Prenatal genetic test
    • 5.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2.5. Electrophoresis
    • 5.4.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2.6. Others
    • 5.4.2.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.3. Hb variants
    • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3.2. Blood test
    • 5.4.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3.3. Genetic test
    • 5.4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3.4. Prenatal genetic test
    • 5.4.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3.5. Electrophoresis
    • 5.4.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3.6. Others
    • 5.4.3.7. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Hemoglobinopathies Market: Therapy Estimates & Trend Analysis

• 6.1. Therapy Market Share, 2023 & 2030
• 6.2. Segment Dashboard
• 6.3. U.S. Hemoglobinopathies Market by Therapy Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
  • 6.4.1. Thalassemia
    • 6.4.1.1. Market estimates and forecasts 2018 to 2030, (USD million)
    • 6.4.1.2. Alpha
    • 6.4.1.2.1. Market estimates and forecasts 2018 to 2030, (USD million)
    • 6.4.1.2.2. Blood transfusion
    • 6.4.1.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.1.2.2.2. Iron chelation therapy
    • 6.4.1.2.2.3. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.1.2.3. Bone marrow transplant
    • 6.4.1.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.1.2.4. Others
    • 6.4.1.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.1.3. Beta
    • 6.4.1.3.1. Market estimates and forecasts 2018 to 2030, (USD million)
    • 6.4.1.3.2. Blood transfusion
    • 6.4.1.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.1.3.2.2. Iron chelation therapy
    • 6.4.1.3.2.3. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.1.3.3. Bone marrow transplant
    • 6.4.1.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.1.3.4. Others
    • 6.4.1.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Sickle Cell Disease
    • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2.2. Blood transfusion
    • 6.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2.3. Hydroxyurea
    • 6.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2.4. Bone marrow transplant
    • 6.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2.5. Others
    • 6.4.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. (Hb) Variants
    • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3.2. Blood transfusion
    • 6.4.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3.3. Hydroxyurea
    • 6.4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3.4. Bone marrow transplant
    • 6.4.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3.5. Others
    • 6.4.3.6. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. List of key distributors and channel partners
  • 7.3.2. Key customers
  • 7.3.3. Key company heat map analysis, 2023
• 7.4. Company Profiles
  • 7.4.1. Sangamo Therapeutics, Inc.
    • 7.4.1.1. Company overview
    • 7.4.1.2. Financial performance
    • 7.4.1.3. Product benchmarking
    • 7.4.1.4. Strategic initiatives
  • 7.4.2. Global Blood Therapeutics, Inc.
    • 7.4.2.1. Company overview
    • 7.4.2.2. Financial performance
    • 7.4.2.3. Product benchmarking
    • 7.4.2.4. Strategic initiatives
  • 7.4.3. bluebird bio, Inc.
    • 7.4.3.1. Company overview
    • 7.4.3.2. Financial performance
    • 7.4.3.3. Product benchmarking
    • 7.4.3.4. Strategic initiatives
  • 7.4.4. Emmaus Life Sciences Inc.
    • 7.4.4.1. Company overview
    • 7.4.4.2. Financial performance
    • 7.4.4.3. Product benchmarking
    • 7.4.4.4. Strategic initiatives
  • 7.4.5. Pfizer, Inc.
    • 7.4.5.1. Company overview
    • 7.4.5.2. Financial performance
    • 7.4.5.3. Product benchmarking
    • 7.4.5.4. Strategic initiatives
  • 7.4.6. Novartis AG
    • 7.4.6.1. Company overview
    • 7.4.6.2. Financial performance
    • 7.4.6.3. Product benchmarking
    • 7.4.6.4. Strategic initiatives
  • 7.4.7. Prolong Pharmaceuticals, LLC
    • 7.4.7.1. Company overview
    • 7.4.7.2. Financial performance
    • 7.4.7.3. Product benchmarking
    • 7.4.7.4. Strategic initiatives
  • 7.4.8. Bioverativ Inc.
    • 7.4.8.1. Company overview
    • 7.4.8.2. Financial performance
    • 7.4.8.3. Product benchmarking
    • 7.4.8.4. Strategic initiatives
  • 7.4.9. Celgene Corp.
    • 7.4.9.1. Company overview
    • 7.4.9.2. Financial performance
    • 7.4.9.3. Product benchmarking
    • 7.4.9.4. Strategic initiatives

관련자료